Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Diabetes Mellitus, Type 2, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetes Complications;Myopia, Degenerative, Date of authorisation: 22/01/2007, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): GONAL-f, follitropin alfa, Anovulation;Reproductive Techniques, Assisted;Infertility, Female;Hypogonadism, Date of authorisation: 20/10/1995, Revision: 26, Status: Authorised

Modelling and simulation: questions and answers

Timetable: Annual renewal application of conditional marketing authorisation

Timetable: Type II variation and worksharing application weekly assessment

Patients' and Consumers' Working Party

Healthcare Professionals' Working Party

Union Product Database: release notes